Document is current
Any future updates will be listed below
-
Authors
Youngblood, Mark W. https://orcid.org/0000-0002-1044-8015
Kumari, Abha https://orcid.org/0000-0003-4299-3699
Kang, Yoon-Tae
Gould, Andrew
Habashy, Karl
Gomez, Mateo
Lingamarla, Harika https://orcid.org/0009-0006-5992-957X
Morey, Trevor
Chen, Li
Congivaram, Harrshavasan
Ward, Rachel
Zhang, Hui https://orcid.org/0000-0001-6825-5649
Sears, Thomas K. https://orcid.org/0000-0003-3834-2439
McCortney, Kathleen https://orcid.org/0000-0001-7085-830X
Pituch, Katarzyna C.
Torres Ponce, Elena M.
Zarrieneh, Ashkan
Nieves, Mariana
Vandermolen, Sarah
Primdahl, Ditte
Dixit, Karan
Lukas, Rimas V.
Kumthekar, Priya
Dmello, Crismita https://orcid.org/0000-0002-1688-9663
Bouchoux, Guillaume
Canney, Michael
Amidei, Christina
Stupp, Roger https://orcid.org/0000-0002-5483-3118
Nagrath, Sunitha https://orcid.org/0000-0002-1497-7977
Sonabend, Adam M. https://orcid.org/0000-0002-8347-1945
- License Information
-
More Information
Article History
Received: 14 March 2025
Accepted: 20 October 2025
First Online: 16 December 2025
Competing interests
: A.M.S. is a paid consultant for Carthera and EnClear Therapies. A.M.S. and R.S have received funding support from Carthera and Agenus Bio, and in-kind support by Agenus, Carthera, and BMS. R.S. serves as a member of the scientific advisory board of Alpheus Medical, Carthera, and has provided consultancy to AstraZeneca, Boston Scientific, Novartis and Novocure. RS has equity in Alpheus Medical and Carthera. M.C. and G.B. are full-time employees of Carthera. M.C. has patents and equity interests in Carthera related to this technology. All other authors declare no competing interests.
